Novo Nordisk’s popular diabetes and obesity medications, Ozempic and Wegovy, have been listed on the Food and Drug Administration’s drug shortage list for over two years. However, as of Wednesday, all doses of semaglutide, the active ingredient in these medications, are now listed as available on the FDA’s website. This development raises the possibility that the medications could soon be removed from the shortage list entirely, which could have implications for compounding pharmacies and patients who rely on compounded drugs.
Semaglutide is the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy. Different doses of semaglutide have been intermittently listed in shortage over the past two years. With all doses now marked as available, the FDA is in discussions with Novo to determine if the company can adequately meet the demand for these medications moving forward. It’s important to note that the “available” designation does not necessarily mean that the drug is no longer in shortage.
FDA spokesperson Amanda Hills stated that the agency is currently assessing whether the demand for semaglutide exceeds the available supply. The decision to remove the medication from the shortage list will depend on the outcome of these discussions between the FDA and Novo.
It’s crucial for patients and healthcare providers to stay informed about the availability of these important medications. The potential resolution of the shortage could bring relief to those who rely on Ozempic and Wegovy for managing their diabetes and obesity. As the situation evolves, it will be important to monitor updates from both Novo Nordisk and the FDA regarding the status of semaglutide and its availability in the market.
